In a context of severe economic limitations and a tightening of the blockade, Cuba takes a decisive step to support care for cancer patients. The AICA Laboratories cytostatic drug plant restarted its production operations after completing an investment process aimed at expanding its capacity, news that reaffirms the Cuban State's commitment to prioritizing the life and health of its people.
The president of BioCubaFarma, Mayda Mauri Pérez, welcomed the Minister of Public Health, José Angel Portal Miranda, to the facility during a visit that highlighted the integrated work between the biopharmaceutical industry, the Ministry of Public Health (Minsap), and the Cuban government—a key factor in achieving this reactivation despite the current complex situation.
According to a Facebook post by the biopharmaceutical group, during the tour, specialists explained that the restart is a phased and controlled process, in which each production phase is activated gradually to ensure technological stability and the quality of the medications.
The plant, now with increased capacity, is responsible for supplying 16 cytostatic drugs to the National Program for the Care of Cancer Patients. Production will resume prioritizing those medications of greatest clinical criticality, according to the schedules agreed upon with the Ministry of Public Health.
Attending the restart of operations at the cytostatic drug plant of Laboratorios AICA, Portal Miranda noted that, despite economic constraints, its reopening will contribute to ensuring the availability of medications for cancer treatment.
For her part, Mayda Mauri Pérez emphasized the current situation and highlighted the strong alliance between the biopharmaceutical and healthcare sectors as an essential pillar for maintaining the supply of cancer medications to the Cuban population, despite the intensification of the economic, commercial, and financial blockade imposed by the United States.
The visit also included the participation of oncologists, who exchanged views with management on therapeutic priorities, thus ensuring that production directly responds to the clinical needs of patients.
The reactivation of this plant is not an isolated event: it is a clear example of how the Cuban biotechnology industry and the public health system work in complete partnership, under a single objective: guaranteeing the availability of essential medications at the most critical time. In a country facing shortages induced from abroad, each drug produced in this plant represents sovereignty, hope and a commitment to the right to health for all Cubans.
